We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Seres Therapeutics Inc | NASDAQ:MCRB | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.03542 | 4.60% | 0.805415 | 0.781 | 0.8067 | 0.8225 | 0.7651 | 0.77 | 3,871,302 | 00:47:45 |
Delaware
|
|
001-37465
|
|
27-4326290
|
(State or other jurisdiction of
|
|
(Commission
|
|
(IRS Employer
|
incorporation)
|
|
File Number)
|
|
Identification No.)
|
101 Cambridgepark Drive
|
|
|
Cambridge, MA
|
|
02140
|
(Address of principal executive offices)
|
|
(Zip Code)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☒
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
MCRB
|
Nasdaq Global Select Market
|
Exhibit
No.
|
Description
|
|
|
Press Release issued by Seres Therapeutics, Inc., dated August 6, 2024.
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
|
|
SERES THERAPEUTICS, INC.
|
|||
|
|
|
|||
Date:
|
August 6, 2024
|
|
By:
|
/s/ Eric D. Shaff
|
|
|
|
|
Name:
|
Eric D. Shaff
|
|
|
|
|
Title:
|
President and Chief Executive Officer
|
• |
Payment of $100M, less approximately $20M in settlement of net obligations payable to Nestlé at closing
|
• |
Prepayment of a $60M milestone payment at closing
|
• |
Installment payments of $50M in January 2025, and $25M (less up to approximately $1.5M in employment related payments to Nestlé), in July 2025, subject to Seres’ material compliance with transition obligations
|
• |
Future milestone payments based on VOWST worldwide net sales as follows:
|
o |
$125M upon achievement of annual worldwide net sales of $400M; and
|
o |
$150M upon achievement of annual worldwide net sales of $750M
|
1 Year Seres Therapeutics Chart |
1 Month Seres Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions